Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis.

Sugimoto T, Nakamura T, Nakamura Y, Isogai Y, Shiraki M

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA10 Oct 2013Cited by 43 (Europe PMC)

PMID24108429PMCIDPMC3923119DOI10.1007/s00198-013-2516-1PepBankPUB-24108429

Read at source PubMedAsk about this study

Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanNon-randomized trialPharmacokinetics
In women with osteoporosis, post-injection parameter changes with teriparatide were similar across data collection weeks.
In plain wordsIn women with osteoporosis, changes after teriparatide injections were similar across measurement weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeReproducibility of post-injection parameter changes
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
56.5 μg once weekly · injection · 24 weeksAs given in this study (human).
Source sentences
Summary
Similar 24 h changes in each parameter after injection of teriparatide were observed in each data collection week.
2 context sentences(design, population, supporting numbers)
Summary · context
Changes in bone turnover markers with weekly 56.5 μg teriparatide injections for 24 weeks were investigated in women with osteoporosis.
Summary · context
The changes were evaluated by comparison with the data at 0 h in each data collection week.
Report a problemFND-2410842901
02HumanNon-randomized trialActivity measurement
In women with osteoporosis, serum calcium increased transiently after teriparatide injection and then returned to baseline.
In plain wordsIn women with osteoporosis, blood calcium rose briefly after teriparatide injection and then returned to baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedAcute serum calcium
Study
n: not reported in source
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
56.5 μg once weekly · injection · 24 weeksAs given in this study (human).
Source sentences
Summary
Serum calcium increased transiently, and intact PTH decreased 4-8 h after injection; serum calcium subsequently returned to baseline levels.
2 context sentences(design, population, supporting numbers)
Summary · context
Changes in bone turnover markers with weekly 56.5 μg teriparatide injections for 24 weeks were investigated in women with osteoporosis.
Summary · context
The changes were evaluated by comparison with the data at 0 h in each data collection week.
Report a problemFND-2410842902
03HumanNon-randomized trialActivity measurement
In women with osteoporosis, intact PTH decreased 4-8 hours after teriparatide injection compared with baseline.
In plain wordsIn women with osteoporosis, intact PTH decreased after teriparatide injection compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseAcute intact PTH
Study
n: not reported in source
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
56.5 μg once weekly · injection · 24 weeksAs given in this study (human).
Source sentences
Summary
Serum calcium increased transiently, and intact PTH decreased 4-8 h after injection; serum calcium subsequently returned to baseline levels.
2 context sentences(design, population, supporting numbers)
Summary · context
Changes in bone turnover markers with weekly 56.5 μg teriparatide injections for 24 weeks were investigated in women with osteoporosis.
Summary · context
The changes were evaluated by comparison with the data at 0 h in each data collection week.
Report a problemFND-2410842903
04HumanNon-randomized trialActivity measurement
In women with osteoporosis, calcium levels decreased during 24 weeks of once-weekly teriparatide injections.
In plain wordsIn women with osteoporosis, calcium levels decreased during 24 weeks of weekly teriparatide injections.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum calcium over treatment
Study
n: not reported in source
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
56.5 μg once weekly · injection · 24 weeksAs given in this study (human).
Source sentences
Summary
Calcium and intact PTH levels decreased for 24 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
Changes in bone turnover markers with weekly 56.5 μg teriparatide injections for 24 weeks were investigated in women with osteoporosis.
Summary · context
The changes were evaluated by comparison with the data at 0 h in each data collection week.
Report a problemFND-2410842904
05HumanNon-randomized trialActivity measurement
In women with osteoporosis, intact PTH decreased during 24 weeks of once-weekly teriparatide injections.
In plain wordsIn women with osteoporosis, intact PTH decreased during 24 weeks of weekly teriparatide injections.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseIntact PTH over treatment
Study
n: not reported in source
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
56.5 μg once weekly · injection · 24 weeksAs given in this study (human).
Source sentences
Summary
Calcium and intact PTH levels decreased for 24 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
Changes in bone turnover markers with weekly 56.5 μg teriparatide injections for 24 weeks were investigated in women with osteoporosis.
Summary · context
The changes were evaluated by comparison with the data at 0 h in each data collection week.
Report a problemFND-2410842905
06HumanNon-randomized trialActivity measurement
In women with osteoporosis, serum osteocalcin decreased at 24 hours after teriparatide injection compared with baseline.
In plain wordsIn women with osteoporosis, serum osteocalcin decreased after teriparatide injection compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum osteocalcin at 24 hours
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · injection · 24 weeksAs given in this study (human).
Source sentences
Summary
Although serum osteocalcin decreased at 24 h, it was significantly increased at 4 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
Changes in bone turnover markers with weekly 56.5 μg teriparatide injections for 24 weeks were investigated in women with osteoporosis.
Summary · context
The changes were evaluated by comparison with the data at 0 h in each data collection week.
Report a problemFND-2410842906
07HumanNon-randomized trialActivity measurement
In women with osteoporosis, serum osteocalcin was significantly increased at 4 weeks of once-weekly teriparatide injections.
In plain wordsIn women with osteoporosis, serum osteocalcin increased at 4 weeks of weekly teriparatide injections.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum osteocalcin at four weeks
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · injection · 24 weeksAs given in this study (human).
Source sentences
Summary
Although serum osteocalcin decreased at 24 h, it was significantly increased at 4 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
Changes in bone turnover markers with weekly 56.5 μg teriparatide injections for 24 weeks were investigated in women with osteoporosis.
Summary · context
The changes were evaluated by comparison with the data at 0 h in each data collection week.
Report a problemFND-2410842907
08HumanNon-randomized trialActivity measurement
In women with osteoporosis, P1NP decreased transiently after teriparatide injection and then increased significantly at 24 hours.
In plain wordsIn women with osteoporosis, P1NP fell briefly after teriparatide injection and then increased compared with baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedAcute P1NP response
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · injection · 24 weeksAs given in this study (human).
Source sentences
Summary
P1NP decreased transiently and then increased significantly at 24 h.
2 context sentences(design, population, supporting numbers)
Summary · context
Changes in bone turnover markers with weekly 56.5 μg teriparatide injections for 24 weeks were investigated in women with osteoporosis.
Summary · context
The changes were evaluated by comparison with the data at 0 h in each data collection week.
Report a problemFND-2410842908
09HumanNon-randomized trialActivity measurement
In women with osteoporosis, P1NP was significantly increased at 4 weeks of once-weekly teriparatide injections.
In plain wordsIn women with osteoporosis, P1NP increased at 4 weeks of weekly teriparatide injections.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseP1NP at four weeks
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · injection · 24 weeksAs given in this study (human).
Source sentences
Summary
P1NP was significantly increased at 4 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
Changes in bone turnover markers with weekly 56.5 μg teriparatide injections for 24 weeks were investigated in women with osteoporosis.
Summary · context
The changes were evaluated by comparison with the data at 0 h in each data collection week.
Report a problemFND-2410842909
10HumanNon-randomized trialActivity measurement
In women with osteoporosis, urinary NTX increased transiently after teriparatide injection and then decreased at 24 hours.
In plain wordsIn women with osteoporosis, urinary NTX rose briefly after teriparatide injection and then decreased.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedAcute urinary NTX response
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · injection · 24 weeksAs given in this study (human).
Source sentences
Summary
Urinary NTX and DPD were significantly increased transiently and then decreased at 24 h.
2 context sentences(design, population, supporting numbers)
Summary · context
Changes in bone turnover markers with weekly 56.5 μg teriparatide injections for 24 weeks were investigated in women with osteoporosis.
Summary · context
The changes were evaluated by comparison with the data at 0 h in each data collection week.
Report a problemFND-2410842910
11HumanNon-randomized trialActivity measurement
In women with osteoporosis, urinary DPD increased transiently after teriparatide injection and then decreased at 24 hours.
In plain wordsIn women with osteoporosis, urinary DPD rose briefly after teriparatide injection and then decreased.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedAcute urinary DPD response
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · injection · 24 weeksAs given in this study (human).
Source sentences
Summary
Urinary NTX and DPD were significantly increased transiently and then decreased at 24 h.
2 context sentences(design, population, supporting numbers)
Summary · context
Changes in bone turnover markers with weekly 56.5 μg teriparatide injections for 24 weeks were investigated in women with osteoporosis.
Summary · context
The changes were evaluated by comparison with the data at 0 h in each data collection week.
Report a problemFND-2410842911
12HumanNon-randomized trialActivity measurement
In women with osteoporosis, urinary DPD decreased significantly at 4 weeks of once-weekly teriparatide injections.
In plain wordsIn women with osteoporosis, urinary DPD decreased at 4 weeks of weekly teriparatide injections.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseUrinary DPD at four weeks
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg once weekly · injection · 24 weeksAs given in this study (human).
Source sentences
Summary
The urinary DPD level decreased significantly at 4 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
Changes in bone turnover markers with weekly 56.5 μg teriparatide injections for 24 weeks were investigated in women with osteoporosis.
Summary · context
The changes were evaluated by comparison with the data at 0 h in each data collection week.
Report a problemFND-2410842912

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.